About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 331 record(s)
Req # A-2022-001645
Correspondence relating to any abbreviated new drug submission (ANDS) filed since December 1, 2022 where the dosage strength is 0.1 or 0.2 mg desmopressin in tablet form.Organization: Health Canada
April 2023
Req # A-2022-001647
Correspondence relating to any abbreviated new drug submission (ANDS) filed since December 1, 2022 where the dosage strength is 15 µg/ml desmopressin in intravenous / subcutaneous dosage form.Organization: Health Canada
April 2023
Req # A-2022-001648
Correspondence relating to any abbreviated new drug submission (ANDS) filed since December 1, 2022 where the dosage strength is 4 µg/ml desmopressin in the form of an injection.Organization: Health Canada
April 2023
Req # A-2022-001652
Correspondence relating to any abbreviated new drug submission (ANDS) filed since December 1, 2022 where the dosage strength is 25 µg or 50 µg desmopressin.Organization: Health Canada
April 2023
Req # A-2022-001653
Correspondence relating to any abbreviated new drug submission (ANDS) filed since December 1, 2022 where the dosage strength is 10 µg desmopressin in intranasal dosage form.Organization: Health Canada
April 2023
Req # A-2023-000012
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Viladozone. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Viladozone which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Viladozone.Organization: Health Canada
April 2023
Req # A-2023-000015
All acknowledgment letters issued by Health Canada confirming receipt of Abbreviated New Drug Submissions (ANDS) for a drug containing Ivacaftor as medicinal ingredient. The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug containing Ivacaftor as medicinal ingredient. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for the generic drug containing Ivacaftor as medicinal ingredient. The strength (s) and dosage form of any and all generic drugs containing Ivacaftor as medicinal ingredient.Organization: Health Canada
April 2023
Req # A-2023-000029
All records conducted by Health Canada between January 2019 and March 2023 regarding the usage of Messenger Ribonucleic Acid (mRNA) vaccines in livestock.Organization: Health Canada
April 2023
Req # A-2021-001192
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-112624-851.Organization: Health Canada
April 2023
Req # A-2022-000318
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102891-541.Organization: Health Canada
April 2023